Selank
Adults · Russian Selank 0.15% nasal-drop leaflet
Selank has a Russian 0.15% nasal-drop product. This reference retains the manufacturer’s product-specific drop count. Adults · Russian Selank 0.15% nasal-drop leaflet.
Peptide dosing library
Browse peptide dose references, source-linked schedules and downloadable charts. Explore the science with myPeptides. – Page 7
Semaglutide
Adults · Weight management · US Wegovy injection label
A reference to the US adult weight-management injection schedule: initiation, maintenance options and the additional 7.2 mg option in the 2026 label.
Semax
Adults · Selected indication in Russian Semax 0.1% leaflet
Semax has a Russian 0.1% nasal-drop product. This card selects the leaflet’s adult cerebrovascular cognitive-use schedule. Adults · Selected indication in Russian Semax 0.1% leaflet.
Sermorelin
Historical human studies · No established adult longevity dosing schedule
Sermorelin has historical paediatric GH-deficiency studies. They do not establish an adult longevity or wellness regimen. Historical human studies · No established adult longevity dosing schedule.
SLU-PP-332
SubQ and oral context · Preclinical evidence · Human regimens not established
A small-molecule ERR agonist investigated in mouse models. The cited studies do not establish oral or injectable human doses.
SNAP-8
Cosmetic evidence gap · No established human dosing schedule
SNAP-8 is an acetyl-octapeptide cosmetic ingredient. An independently validated human peptide dose is not established. Cosmetic evidence gap · No established human dosing schedule.
Somatropin (HGH 191AA)
Confirmed adult GH deficiency · US Genotropin · Non-weight-based option
Somatropin is 191-amino-acid human growth hormone. This reference selects an adult GH-deficiency label approach. Confirmed adult GH deficiency · US Genotropin · Non-weight-based option.
SS-31
Barth syndrome · Body weight ≥30 kg · US Forzinity label
SS-31 is elamipretide. This reference covers the US Forzinity label for Barth syndrome, not general mitochondrial wellness. Barth syndrome · Body weight ≥30 kg · US Forzinity label.
Survodutide
Adults without diabetes · SubQ · 2024 phase 2 obesity trial
SubQ target-dose arms from the 46-week obesity trial, with the study’s escalation and maintenance periods kept distinct.
TB-4 (Thymosin beta-4)
Formulation-specific trials · No established human subq dosing schedule
TB-4 is full-length thymosin beta-4. Human ocular, skin and IV studies do not establish a routine SubQ injury regimen. Formulation-specific trials · No established human subq dosing schedule.
TB-500
Fragment evidence gap · No established human dosing schedule
This card uses TB-500 for Ac-LKKTETQ, a seven-residue fragment. Full-length thymosin beta-4 trials do not establish its dose. Fragment evidence gap · No established human dosing schedule.
TB-500 Fragment (17-23)
Animal wound models · No established human dosing schedule
Unacetylated LKKTETQ is a seven-residue TB-4 fragment. Mouse wound studies do not establish a human dose. Animal wound models · No established human dosing schedule.